[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336385-105":59,"doc-detail-336385-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognosis-of-gleason-score-8-prostatic-adenocarcinoma-in-needle-biopsies-a-nationwide-population-based-study","Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies - a nationwide population-based study","","A nationwide population-based cohort assessed prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) for men diagnosed with Gleason score 3+5=8, 4+4=8, and 5+3=8 acinar adenocarcinoma on needle biopsy. Survival analysis used Prostate Cancer data Base Sweden 5.0 with PCSM and ACM at 5 and 10 years, adjusting Cox models for socioeconomic factors, stage, and primary treatment. In 18,281 needle-biopsy cases (11%), 5+3 showed higher PCSM than 4+4 and 3+5 across follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognosis-of-gleason-score-8-prostatic-adenocarcinoma-in-needle-biopsies-a-nationwide-population-based-study/336385/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognosis-of-gleason-score-8-prostatic-adenocarcinoma-in-needle-biopsies-a-nationwide-population-based-study/336385.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s objective regarding Gleason score 8?","Question",{"text":112,"@type":113},"To evaluate prostate cancer-specific and all-cause mortality across subgroups of Gleason score 8 by analyzing the 3+5, 4+4, and 5+3 combinations in a large population-based cohort while accounting for diagnosis date and treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which dataset and statistical approach were used for survival analysis?",{"text":117,"@type":113},"The study used Prostate Cancer data Base Sweden 5.0 for survival analysis, with PCSM and ACM at 5 and 10 years. Multivariable Cox regression models adjusted for socioeconomic factors, stage, and primary treatment type.",{"name":119,"@type":110,"acceptedAnswer":120},"How did prostate cancer-specific mortality differ among Gleason 3+5, 4+4, and 5+3?",{"text":121,"@type":113},"At 5 years, PCSM was 0.10 for 3+5, 0.22 for 4+4, and 0.32 for 5+3; at 10 years it was 0.19, 0.34, and 0.44, respectively. The study reported significantly higher PCSM for 5+3 compared with 4+4 and 3+5, and for 4+4 compared with 3+5.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336385,1790851592,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Virchows Archiv (2024) 484:995–1003  \n[https://doi.org/10.1007/s00428-024-03810-y](https://doi.org/10.1007/s00428-024-03810-y)  \nPrognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population‑based study  \nLars Egevad1 · Chiara Micoli2 · Brett Delahunt1,3 · Hemamali Samaratunga4 · Andri Wilberg Orrason5 · Hans Garmo5,6 · Pär Stattin5 · Martin Eklund2  \nReceived: 11 March 2024 / Revised: 9 April 2024 / Accepted: 19 April 2024 / Published online: 29 April 2024 © The Author(s) 2024  \nAbstract  \nA 5-tier grouping of Gleason scores has recently been proposed. Studies have indicated prognostic heterogeneity within these groups. We assessed prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) for men diagnosed with Gleason score 3 + 5 = 8, 4 + 4 = 8 and 5 + 3 = 8 acinar adenocarcinoma on needle biopsy in a population-based national cohort. The Prostate Cancer data Base Sweden 5.0 was used for survival analysis with PCSM and ACM at 5 and 10 years as endpoints. Multivariable Cox regression models controlling for socioeconomic factors, stage and primary treatment type were used for PCSM and ACM. Among 199,620 men reported with prostate cancer in 2000–2020, 172,112 were diagnosed on needle biopsy. In 18,281 (11%), there was a Gleason score of 8 in needle biopsies, including a Gleason score of 3 + 5, 4 + 4 and 5 + 3 in 11%, 86% and 2.3%, respectively. The primary treatment was androgen deprivation therapy (55%), deferred treatment (8%), radical prostatectomy (16%) or radical radiotherapy (21%). PCSM in men with Gleason scores of 3 + 5, 4 + 4 and 5 + 3 at 5 years of follow-up was 0.10 (95% CI 0.09–0.12), 0.22 (0.22–0.23) and 0.32 (0.27–0.36), respectively, and at 10 years 0.19 (0.17–0.22), 0.34 (0.33–0.35) and 0.44 (0.39–0.49), respectively. There was a significantly higher PCSM after 5 and 10 years in men with Gleason score 5 + 3 cancers than in those with 4 + 4 and in Gleason score 4 + 4 cancers than in those with 3 + 5. Grouping of Gleason scores will eliminate the prognostic granularity of Gleason scoring, thus diminishing the prognostic significance of this proposed grading system.  \nKeywords Gleason grade · Mortality · Needle biopsy · Prostate cancer  \n* Lars Egevad [lars.egevad@ki.se](lars.egevad@ki.se)  \n1 Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, 171 76 Stockholm, Sweden  \n2 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden  \n3 Malaghan Institute of Medical Research, Wellington, New Zealand  \n4 Aquesta Uropathology and University of Queensland, Brisbane, QLD, Australia  \n5 Department of Surgical Sciences, Uppsala University, Uppsala, Sweden  \n6 Regional Cancer Centre Mid-Sweden, Uppsala University Hospital, Uppsala, Sweden  \nBackground  \nProstate adenocarcinoma is often morphologically heterogenous, consisting of two or more grades or patterns as defined in the Gleason grading system and its various amendments. Gleason scoring, which is the sum of the primary and secondary grades, was specifically designed to take the various grades present into account in order to provide an overall prognostic assessment of individual cases and requires assessment of the whole tumour. It is an important strength of Gleason grading that it factors in the heterogeneity of the tumour. While combinations of Gleason grade do provide an overview of the morphology of the tumour, the Gleason sum score is less granular on its own, and it is evident that identical individual Gleason scores may be achieved through the presence of apparently unrelated grade combinations. This issue is especially evident in cancers showing morphology of the higher grades. While Gleason scoring has the effect of masking morphological complexity, quotation  \nof the composite grades in conjunction with the score, e.g.  \n3 + 4 = 7, does provide data that are of clinical utility when reporting a tumour as Gleason score 7. Such informatio","cbCaifANnx6Eiqkb","https://ap.wps.com/l/cbCaifANnx6Eiqkb","pdf",1635410,"English","# Abstract\n# Background\n# Aim of the study\n# Materials and methods","[{\"question\":\"What was the study’s objective regarding Gleason score 8?\",\"answer\":\"To evaluate prostate cancer-specific and all-cause mortality across subgroups of Gleason score 8 by analyzing the 3+5, 4+4, and 5+3 combinations in a large population-based cohort while accounting for diagnosis date and treatment.\"},{\"question\":\"Which dataset and statistical approach were used for survival analysis?\",\"answer\":\"The study used Prostate Cancer data Base Sweden 5.0 for survival analysis, with PCSM and ACM at 5 and 10 years. Multivariable Cox regression models adjusted for socioeconomic factors, stage, and primary treatment type.\"},{\"question\":\"How did prostate cancer-specific mortality differ among Gleason 3+5, 4+4, and 5+3?\",\"answer\":\"At 5 years, PCSM was 0.10 for 3+5, 0.22 for 4+4, and 0.32 for 5+3; at 10 years it was 0.19, 0.34, and 0.44, respectively. The study reported significantly higher PCSM for 5+3 compared with 4+4 and 3+5, and for 4+4 compared with 3+5.\"}]","Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies - a nationwide population-based study | PDF",1790014803,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5127f5fb4bd4287b040110ac0be18449.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bce95e06a597888e6b241de2de1170e.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ec64ef2a1eea66bf0659ae5a89ffb56.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b8dba7b611f5c0eb5ee961085c1ec9e.webp",980,1301]